Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

OBJECTIVE: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes the proinflammatory cytokine IL-17A, has been approved in Europe in 2015 for the treatment of adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clinicoecon Outcomes Res
Glavni autori: Colombo, Giorgio L, Di Matteo, Sergio, Martinotti, Chiara, Jugl, Steffen M, Gunda, Praveen, Naclerio, Mariantonietta, Bruno, Giacomo M
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2018
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6121773/
https://ncbi.nlm.nih.gov/pubmed/30214261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S171560
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items